FDA records identify Just Medical Devices (Tianjin) Co., Ltd. as the applicant behind K253961, the SK Knee System, with a decision date of September 1, 2026 and a decision description of Substantially Equivalent. The filing sits in regulation 21 CFR 888.3560, product code JWH, advisory committee Orthopedic, and was submitted as a Traditional 510(k) with a Summary rather than a third-party review. The company’s own published material places the firm in joint prostheses, clinical surgical robots and biomaterials, and lists hip and knee reconstruction among its product lines. [1][2][6][7]
The K253961 filing and its scope
The FDA record for K253961 lists the device as SK Knee System, applicant Just Medical Devices (Tianjin) Co., Ltd., with date received December 10, 2025 and decision date September 1, 2026. The decision code is SESE and the decision description Substantially Equivalent; the clearance type is Traditional, the third-party flag is N, and the statement or summary field reads Summary. The regulation is 21 CFR 888.3560, described as Knee Joint Patellofemorotibial Polymer/Metal/Polymer Semi-Constrained Cemented Prosthesis, Class II, product code JWH, with Orthopedic as both advisory committee and review advisory committee. [1][2]
The FDA letter dated September 1, 2026 addresses the applicant through Robert Poggie, President, BioVera, Inc., at an address in Notre-Dame-De-L'Ile-Perrot, Quebec, Canada, and repeats the trade name SK Knee System, regulation number 21 CFR 888.3560, regulatory class Class II and product code JWH. The letter carries a dated line of July 31, 2026. The correspondence address in that letter is not a statement of the applicant’s headquarters. [2]
Testing basis described in the filing
The non-clinical and/or clinical tests summary in the FDA record states that pre-clinical performance testing was performed for the SK Knee System per the FDA guidance document on knee joint patellofemorotibial and femorotibial metal/polymer porous-coated uncemented prostheses, ASTM and ISO consensus standards, and publicly available information. The same passage states that these do not raise different issues of safety and effectiveness. No clinical outcome results, performance figures or patient-selection criteria appear in the numbered records. [2]
Company description from its own publications
The manufacturer’s English-language site describes Just Medical Devices (Tianjin) Co., Ltd. as specializing in joint diseases, with work in joint prostheses, clinical surgical robots and biomaterials, and describes itself as a leading enterprise in artificial joints in China. That page states the company has five R&D centers across Tianjin, Beijing, Shanghai and the United States, and cites a Tianjin Enterprise Key Laboratory and Technology Center. These are the publisher’s characterizations, not FDA findings. [6]
A separate company page states the firm was established in 1958 and describes it as a Chinese manufacturer of hip and knee implants and instruments, integrating R&D, manufacturing, sales, training and service. It lists six product lines: Hip Reconstruction, Knee Reconstruction, Partial Knee Replacement, New Interface, Regenerative Repair and AI Digitalization. The Chinese-language site describes the same joint-disease focus and lists five R&D centers in Tianjin, Beijing, Shanghai and the United States, with a Tianjin enterprise key laboratory and technology center. [7][9]
The manufacturer’s news page carries an item titled “JUST Medical Knee System Receives U.S. FDA 510(k) Clearance,” dated September 3, 2026, and the site also references an RSK High-Flexion Hybrid Revision Knee System case-study item and an SKII PS knee joint prosthesis system item. Those page titles identify product names; the numbered records do not establish clearances, availability or performance for them. [8]
What the collection shows and does not show
As of November 20, 2026, the linked FDA record collection contains one 510(k) entry, K253961, and the decision counts show one SESE decision; the explicitly smaller record sample contains that same single entry. These are counts of the linked filings at that date, not totals for company sales, portfolio breadth or safety performance. No recall records appear in the linked collection. [1]
The Chinese-language site states that, as of January 2025, the company’s products had obtained 54 global Class III medical device registration certificates and that it had filed more than 286 patents worldwide, with sales covering domestic provinces and more than 50 countries and regions. Those figures are the publisher’s statements and are not corroborated by the FDA records reviewed here. Ownership, parentage and brand relationships beyond the named applicant are not established in the numbered sources. [9]
